Hua Medicine is on track to get its first drug candidate into clinical trials. The molecule is a treatment for type 2 diabetes in-licensed from Roche. Hua filed a request for Clinical Trial Approval in September, and it completed its Site Inspection and Dossier Amendment this week – a process that took only one month instead of the usual three-to-four months. According to Hua, the “well-established drug innovation ecosystem” at Zhangjiang High-Tech Park and its own Collaborative Innovation model of drug R&D were the reasons the drug is advancing so rapidly. More details.... Stock Symbol: (SIX: ROG) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});